Clinical studies and real-world evidence have shown that patients taking empagliflozin can experience varying degrees of weight loss. On average, patients might lose around 2 to 3 kilograms (approximately 4.4 to 6.6 pounds) throughout 24 to 52 weeks. However, the extent of weight loss can differ based on several factors, including, dosage, duration of treatment, baseline weight, lifestyle habits, and individual metabolic responses to the drug. It is also worth mentioning that while weight loss can be beneficial, it should be monitored by healthcare providers to ensure it remains within a healthy range. Excessive weight loss or rapid changes in body weight could indicate other underlying issues or adverse reactions that need medical attention. This weight loss is influenced by dosage, duration of use, baseline weight, lifestyle choices, metabolic response, and concurrent use of other medications. Patients should discuss their weight loss goals and any concerns with their healthcare providers to ensure a safe and effective treatment plan.